- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03003988
Physiological Effects of Creatine Supplementation in Active Males (NB4)
January 2, 2017 updated by: Texas A&M University
Effects of 28 Days of Different Forms of Creatine Supplementation on Muscle Creatine, Body Composition and Exercise Performance in Recreationally Active Males
This study was designed to examine how different forms of creatine impact active males.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study examined the effects of different formulations of creatine nitrate on muscle creatine content, body composition, anaerobic exercise capacity, bench press performance and clinical chemistry panels in recreationally active males.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 38 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- participants are apparently healthy and recreationally active males between the ages of 18 and 40;
- participants will need to have at least six months immediate prior history of resistance training on the bench press and leg press or squat;
Exclusion Criteria:
- participants have a history of treatment for metabolic disease (i.e., diabetes), hypertension, hypotension, thyroid disease, arrhythmias and/or cardiovascular disease;
- participants are currently using prescription medications;
- participants have a history of smoking;
- participants drink excessively (i.e., 12 drinks per week or more);
- participants have a recent history of creatine supplementation within six weeks of the start of supplementation;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Creatine monohydrate
Creatine monohydrate (6.0 g.) + dextrose (0.5 g.)
|
Creatine monohydrate (6.0 g) + dextrose (0.5 g)
|
Active Comparator: Creatine nitrate
Creatine nitrate (5.0 g. creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio).
|
Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
|
Placebo Comparator: Placebo
6.5 g. dextrose
|
Placebo (6.5 g dextrose)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects of 28 Days of Different Forms of Creatine Supplementation on Body Water
Time Frame: 28 Days
|
Assessing Body Water through Bioelectrical Impedance Analysis (BIA)
|
28 Days
|
Effects of 28 Days of Different Forms of Creatine Supplementation on Body Composition
Time Frame: 28 Days
|
Assessing Body Compositing through Dual-Energy X-Ray Absorptiometry (DXA)
|
28 Days
|
Effects of 28 Days of Different Forms of Creatine Supplementation on intramuscular creatine
Time Frame: 28 Days
|
Assessing intramuscular creatine using standard spectrophotometric methods using a microplate spectrophotometer
|
28 Days
|
Effects of 28 Days of Different Forms of Creatine Supplementation on intramuscular phosphocreatine
Time Frame: 28 Days
|
Assessing intramuscular phosphocreatine using standard spectrophotometric methods using a microplate spectrophotometer
|
28 Days
|
Effects of 28 Days of Different Forms of Creatine Supplementation on intramuscular ATP
Time Frame: 28 Days
|
Assessing intramuscular Adenosine Triphosphate (ATP) using standard spectrophotometric methods using a microplate spectrophotometer
|
28 Days
|
Effects of 28 Days of Different Forms of Creatine Supplementation on muscular strength
Time Frame: 28 Days
|
Assessing muscular strength through 1 Repetition Maximum (RM) testing
|
28 Days
|
Effects of 28 Days of Different Forms of Creatine Supplementation on muscular endurance
Time Frame: 28 Days
|
Assessing muscular endurance through repetition to failure testing
|
28 Days
|
Effects of 28 Days of Different Forms of Creatine Supplementation on anaerobic capacity
Time Frame: 28 Days
|
Assessing anaerobic capacity through 6 x 6 second sprints followed by a 30 second sprint on a Wingate bicycle ergometer
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects of 28 Days of Different Forms of Creatine Supplementation on training volume (weight lifted x number of repetitions x number of sets)
Time Frame: 28 Days
|
Assessing training volume using a calculator
|
28 Days
|
Effects of 28 Days of Different Forms of Creatine Supplementation on self-reported side effects
Time Frame: 28 Days
|
Assessing self-reported side effects using a side effects questionnaire
|
28 Days
|
Effects of 28 Days of Different Forms of Creatine Supplementation on blood
Time Frame: 28 Days
|
Measure standard clinical chemistry panels in the blood to evaluate safety
|
28 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard B Kreider, PhD, Texas A&M University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
December 14, 2016
First Submitted That Met QC Criteria
December 22, 2016
First Posted (Estimate)
December 28, 2016
Study Record Updates
Last Update Posted (Estimate)
January 4, 2017
Last Update Submitted That Met QC Criteria
January 2, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- IRB2014-0503FX
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dietary Supplementation
-
California Baptist UniversityCompletedDietary SupplementationUnited States
-
University of the Incarnate WordCompleted
-
Brock UniversityUniversity of TorontoNot yet recruitingExercise | Dietary Supplementation
-
Colorado State UniversityVirginia Polytechnic Institute and State University; University of North Carolina... and other collaboratorsCompletedDietary Rice Bran SupplementationUnited States, Nicaragua
-
University of AberdeenCompletedDietary Supplementation During ExerciseUnited Kingdom
-
Colorado State UniversityUniversity of the Sciences, Techniques and Technologies of BamakoCompletedDietary Rice Bran SupplementationUnited States, Mali
-
California Baptist UniversityCompletedDietary SupplementationUnited States
-
University of Central Florida4D, LLCCompletedDietary SupplementationUnited States
-
Singapore Institute for Clinical SciencesCompletedDietary Nitrate SupplementationSingapore
-
International Food Policy Research InstituteFHI 360; AFRICSantéCompletedMaternal Dietary Diversity | Iron-Folic Acid Supplementation | Early Initiation of BreastfeedingUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States